130 related articles for article (PubMed ID: 24313640)
21. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
Trémollieres FA; Pouilles JM; Ribot C
Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
[TBL] [Abstract][Full Text] [Related]
22. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
23. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
24. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
25. The relationship between back pain and future vertebral fracture in postmenopausal women.
Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
[TBL] [Abstract][Full Text] [Related]
26. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
[TBL] [Abstract][Full Text] [Related]
27. Relationships between vertebral fractures, sex hormones and vitamin D in Moroccan postmenopausal women: a cross sectional study.
El Maataoui A; El Maghraoui A; Biaz A; Elmachtani SI; Dami A; Bouhsain S; Mounach A; Chabraoui L; Ouzzif Z
BMC Womens Health; 2015 May; 15():41. PubMed ID: 25968889
[TBL] [Abstract][Full Text] [Related]
28. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
[TBL] [Abstract][Full Text] [Related]
30. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment.
Krol CG; Dekkers OM; Kroon HM; Rabelink TJ; van Hoek B; Hamdy NA
J Bone Miner Res; 2014 Aug; 29(8):1763-9. PubMed ID: 24644003
[TBL] [Abstract][Full Text] [Related]
32. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
33. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
[TBL] [Abstract][Full Text] [Related]
34. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
Cummings SR; Karpf DB; Harris F; Genant HK; Ensrud K; LaCroix AZ; Black DM
Am J Med; 2002 Mar; 112(4):281-9. PubMed ID: 11893367
[TBL] [Abstract][Full Text] [Related]
35. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
36. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
37. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
38. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
Ringe JD; Kipshoven C; Cöster A; Umbach R
Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
[TBL] [Abstract][Full Text] [Related]
39. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
40. Estrogen therapy for osteoporosis in the modern era.
Levin VA; Jiang X; Kagan R
Osteoporos Int; 2018 May; 29(5):1049-1055. PubMed ID: 29520604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
